Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: Partners in a successful MARRIAGE?

Current Medical Research and Opinion

Volumn 20, Issue 3, 2004, Pages 359-367

  Rayner, Brian ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Diabetes mellitus; Dysglycaemia; Hypertension; Insulin resistance; Metabolic syndrome; Moxonidine; Ramipril

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FOSINOPRIL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMIDAZOLINE I1 RECEPTOR; IMIDAZOLINE RECEPTOR AGONIST; INSULIN; LISINOPRIL; LOSARTAN; MOXONIDINE; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HEMODYNAMIC PARAMETERS; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MEDULLA OBLONGATA; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONHUMAN; OUTCOMES RESEARCH; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HUMANS; HYPERTENSION; IMIDAZOLES; INSULIN RESISTANCE; METABOLIC SYNDROME X; RAMIPRIL; RECEPTORS, DRUG; RISK;

EID: 1542615355     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125002991     Document Type: Review

References (68)

1. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors and 12-year mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-44
2. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
3. Becker A, Bos G, de Vegt F, et al. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease - 10-year follow-up of the Hoorn Study. Eur Heart J 2003;24:1406-3
4. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
5. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
6. Reaven G. Syndrome X 10 years after. Drugs 1999;58(Suppl 1):19-20
7. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001;285:2486-97
8. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9
9. Pyörälä K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979;2:131-41
10. Gerstein HC. A disturbed glucose metabolic state (dysglycaemia) is a key factor for cardiovascular events. Eur Heart J 2003;24(Suppl B):B1-B2
11. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-83
12. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of diabetes? JAMA 1990;263:2893-8
13. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-40
14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13
15. Lithell HO, Andersson PE. Antihypertensive treatment in insulin resistant patients. Hypertens Res 1996;19(Suppl 1):S75-S79
16. Moan A, Hoieggen A, Nordby G, Eide IK, Kjeldsen SE. Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? J Hum Hypertens 1995;9(Suppl 5):S45-50
17. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002;288:2981-97
18. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Safety 2001;25:1155-65
19. Metheson AJ, Cheer SM, Goa KL. Perindopril/indapamide 2/0.635 mg/day: a review of its place in the management of hypertension. Drugs 2001;61:1211-29
20. Krum H, Skiba M, Gilbert RE. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Diabetes Med 2003;20:708-12
21. Spence JD, Huff M, Barnett PA. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison. Can J Clin Pharmacol 2000;7:32-7
22. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998;11:1258-65
23. Reneland R, Alvarez E, Andersson PL, et al. Induction of insulin resistance by beta-blockade but not by ACE-inhibition: long-term treatment with atenolol or trandolapril. J Hum Hypertens 2000;14:175-80
24. Hansson L, Zanchetti A, Carruthers SG, et al. for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62
25. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991;265:3255-64
26. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents a systematic review and meta-analysis. JAMA 1997;277:739-45
27. Pahor M, Psaty BM, Alderman MH, et al. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000;23:888-92
28. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-6
29. Niskanen L, Hedner T, Hansson L, et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/β-blocker-based treatment regimen. Diabetes Care 2001;24:2091-6
30. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20
31. Leren P. The cardiovascular effects of alpha-receptor blocking agents. J Hypertens 1992;10(Suppl):S11-14
32. Inoue Y, Kaneko T, Matsumara S, et al. Antihypertensive and metabolic effects of doxazosin in hypertensive patients with concomitant non-insulin-dependent diabetes mellitus. J Int Med Res 1996;24:138-46
33. Shieh SM, Sheu WH, Shen DC, et al. Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992;5:827-31
34. Giugliano D, Acampora R, Marfella R, et al. Hemodynamic and metabolic effects of transdermal clonidine in patients with hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens 1998;11:184-9
35. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
36. Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE). Lancet 2002;359:1004-10
37. Lindholm LH, Dahlöf B, Edelmans JM, et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003;362:619-20
38. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 2000;101:2271-6
39. Gress TW, Nieto FJ, Shamar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000;342:905-12
40. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
41. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9
42. Chobanian A, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289:2560-82
43. Brown MJ, Palmer CJ, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000;356:366-72
44. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000;356:359-65
45. Lithell H, Hansson K, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86
46. Lindholm LH, Ibsen H, Borch-Johnsen B, et al. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86
47. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21:1563-74
48. Julius S, Majahalma S, Palatini P. Antihypertensive treatment of patients with diabetes and hypertension. Am J Hypertens 2001;14:310S-6S
49. Califf RM. Insulin resistance: a global epidemic in need of effective therapies. Eur Heart J Suppl 2003;(Suppl C):C13-C18
50. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): 1. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993;11:309-17
51. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37:1053-9
52. Schachter M. Metabolic effects on moxonidine and other centrally acting antihypertensives. Diabetes Obes Metab 1999;1:317-22
53. 1-imidazoline receptor agonist moxonidine: a new antihypertensive. London: Royal Society of Medicine Press Ltd, 1996:7-30
54. Prichard BNC, Graham BR. The use of moxonidine in the treatment of hypertension. J Hypertens 1997;15(Suppl 1): S47-S55
55. Küppers H, Jäger B, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens 1997;15:93-7
56. Penner SB, Smyth DD. Renal imidazoline preferring sites and sodium excretion in the rat. Br J Clin Pharmacol 1993;108:870-5
57. Kaan EC, Brückner R, Frohly P, et al. Effects of agmatine and moxonidine on glucose metabolism: an integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorders. J Cardiac Risk Factors 1995;5:10-27
58. Rösen P, Ohly P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens 1997;15(Suppl 1):S31-S38
59. 1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens 1997;15(Suppl 1):S9-S23
60. Ernsberger P, Ishizuka T, Liu S, et al. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 1999;288:139-47
61. Yakubu-Madus FE, Johnson WT, Zimmerman KM, et al. Metabolic and hemodynamic effects of moxonidine in the Zucker diabetic rat model of type 2 diabetes. Diabetes 1999;48:1093-100
62. Bernobich E, de Angelis L, Lerin C, Bellini G. The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications. Drugs 2002;62:1295-314
63. Haenni A, Lithell HO. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999;17(Suppl 3): S29-S35
64. Almazov VA, Shlyatko EV, Blagosklonnaya YV, et al. Insulin resistance and arterial hypertension. The influence of moxonidine and metformin therapy. J Hypertens 2000;18(Suppl 2): [abstract 2B.6]
65. Sanjuliani AF, Genelhu-Fagunde V, Barroso SG, et al. Effect of a imidazoline agonist on sympathetic activity and components of the insulin resistance syndrome in obese hypertensive Brazilian patients. J Hypertens 2002;20:S206[abstract]
66. Raji A, Seely EW, Bekins SA, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172-8
67. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2000;23(Suppl 1):S20-S23
68. Waters J, Ashford J, Jäger B, Wonnacott S, Verboom C-N for the OPIC Investigators. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension - results of the TOPIC (Trial of Physiotens in combination) Study. J Clin Basic Cardiol 1999;2:219-24